In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aerie Pharmaceuticals, Inc.. Trade Record

NASDAQ:AERI Aerie Pharmaceuticals, Inc. stock gains 13.39% Exit Feb 6, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart AERI Jan 9, 2019, priceSeries
About Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.05
Entry Date
Jan 9, 2019
Entry Price
39.84
Sell Date
Feb 6, 2019
Sell Price
45.18
Net Gain
13.39%
Hold Time
19 Trading Days